Lim CS - Search Results

1

Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency.

Ko S, Ju MS, Ahn HM, Na JH, Ko WH, Jo M, Kyung M, Lim CS, Ko BJ, Lee WK, Kim YJ, Jung ST. Ko S, et al. Among authors: lim cs. Mol Pharm. 2023 Feb 6;20(2):1247-1255. doi: 10.1021/acs.molpharmaceut.2c00923. Epub 2022 Dec 23. Mol Pharm. 2023. PMID: 36563318

2

Validation of Rapi-Fluor method for glycan profiling and application to commercial antibody drugs.

Lim MS, So MK, Lim CS, Song DH, Kim JW, Woo J, Ko BJ. Lim MS, et al. Among authors: lim cs. Talanta. 2019 Jun 1;198:105-110. doi: 10.1016/j.talanta.2019.01.093. Epub 2019 Jan 25. Talanta. 2019. PMID: 30876537

3

Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.

Yoon HW, Jo M, Ko S, Kwon HS, Lim CS, Ko BJ, Lee JC, Jung ST. Yoon HW, et al. Among authors: lim cs. Mol Immunol. 2019 Oct;114:62-71. doi: 10.1016/j.molimm.2019.07.007. Epub 2019 Jul 20. Mol Immunol. 2019. PMID: 31336250

4

A human antibody against human endothelin receptor type A that exhibits antitumor potency.

Ju MS, Ahn HM, Han SG, Ko S, Na JH, Jo M, Lim CS, Ko BJ, Yu YG, Lee WK, Kim YJ, Jung ST. Ju MS, et al. Among authors: lim cs. Exp Mol Med. 2021 Sep;53(9):1437-1448. doi: 10.1038/s12276-021-00678-9. Epub 2021 Sep 29. Exp Mol Med. 2021. PMID: 34588605 Free PMC article.

5

An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.

Ko S, Park S, Sohn MH, Jo M, Ko BJ, Na JH, Yoo H, Jeong AL, Ha K, Woo JR, Lim C, Shin JH, Lee D, Choi SY, Jung ST. Ko S, et al. Exp Mol Med. 2022 Nov;54(11):1850-1861. doi: 10.1038/s12276-022-00870-5. Epub 2022 Nov 1. Exp Mol Med. 2022. PMID: 36319752 Free PMC article.

6

Glycan-Controlled Human PD-1 Variants Displaying Broad-Spectrum High Binding to PD-1 Ligands Potentiate T Cell.

Ha JY, Chun KJ, Ko S, Lee HW, Hwang OK, Lim CS, Ha K, Ko BJ, Jung ST. Ha JY, et al. Among authors: lim cs. Mol Pharm. 2023 Apr 3;20(4):2170-2180. doi: 10.1021/acs.molpharmaceut.3c00003. Epub 2023 Mar 10. Mol Pharm. 2023. PMID: 36897183

7

Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.

Lee SM, Min SW, Kwon HS, Bae GD, Jung JH, Park HI, Lee SH, Lim CS, Ko BJ, Lee JC, Jung ST. Lee SM, et al. Among authors: lim cs. Sci Rep. 2023 Oct 25;13(1):18275. doi: 10.1038/s41598-023-45491-8. Sci Rep. 2023. PMID: 37880350 Free PMC article.

8

Selection and Characterization of YKL-40-Targeting Monoclonal Antibodies from Human Synthetic Fab Phage Display Libraries.

Kang K, Kim K, Lee SR, Kim Y, Lee JE, Lee YS, Lim JH, Lim CS, Kim YJ, Baek SI, Song DH, Hong JT, Kim DY. Kang K, et al. Among authors: lim cs, lim jh. Int J Mol Sci. 2020 Sep 1;21(17):6354. doi: 10.3390/ijms21176354. Int J Mol Sci. 2020. PMID: 32883029 Free PMC article.

9

Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody.

Kim SI, Kim S, Kim J, Chang SY, Shim JM, Jin J, Lim C, Baek S, Min JY, Park WB, Oh MD, Kim S, Chung J. Kim SI, et al. Int J Mol Sci. 2019 Oct 12;20(20):5073. doi: 10.3390/ijms20205073. Int J Mol Sci. 2019. PMID: 31614869 Free PMC article.

10

Fear of progression, coping strategies, and associated factors among a sample of Malaysian women with breast cancer.

Lim HL, Suhail MK, Lim CS, Daher AM. Lim HL, et al. Among authors: lim cs. Sci Rep. 2025 Jan 6;15(1):922. doi: 10.1038/s41598-024-82143-x. Sci Rep. 2025. PMID: 39762234 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,233 results

Search Page

Filters